Revolution Medicines
RVMD
73 hedge funds and large institutions have $1.03B invested in Revolution Medicines in 2020 Q1 according to their latest regulatory filings, with 73 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
82.5% more ownership
Funds ownership: 0% → 82.5% (+83%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
+$250M |
| 2 |
PS
Peter Svennilson
|
+$221M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$184M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$84.4M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$76.6M |
Top Sellers
RVMD Hedge Fund Activity: Q1 2020 in Review
73 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q1 2020, worth a combined $1.03B.
Buyers outnumbered sellers: 73 funds opened new RVMD positions and 0 closed out — a net gain of 73 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TRV GP III, opening a new position worth an estimated $250M.
- 73 institutional investors held Revolution Medicines (RVMD) as of Q1 2020, up from 0 in Q4 2019.
- Funds reported $1.03B of Revolution Medicines stock for Q1 2020.
- 73 funds opened new Revolution Medicines positions in Q1 2020 and 0 closed out, a net change of +73 holders.
- The largest Revolution Medicines buyer in Q1 2020 was TRV GP III, an estimated $250M added.
Based on aggregated 13F filings for Q1 2020.